Global circRNA expression changes predate clinical and histological improvements of psoriasis patients upon secukinumab treatment

PLoS One. 2022 Sep 29;17(9):e0275219. doi: 10.1371/journal.pone.0275219. eCollection 2022.

Abstract

Psoriasis is a common chronic inflammatory skin disease accompanied by heterogenous clinical and histological features, including a characteristic keratinocyte hyperproliferation and dermal immunogenic profile. In addition, psoriasis is associated with widespread transcriptomic alterations including changes in microRNA (miRNA) and circular RNA (circRNA) abundance, which constitute non-coding RNA (ncRNA) classes with specific regulatory capacities in diverse physiological and pathological processes. However, the knowledge about the expression dynamics of ncRNA during psoriasis treatment is sparse. To elucidate the dynamics of miRNA and circRNA abundance during secukinumab (anti-IL-17A) treatment, we studied their expression patterns in skin biopsies from 14 patients with severe plaque-type psoriasis before and during an 84-day secukinumab therapy at day 0, 4, 14, 42, and 84 using NanoString nCounter technology. We found a comprehensive downregulation of the majority of investigated circRNAs and specific alterations in the miRNA profile, including an upregulation of miR-203a-3p, miR-93-5p, and miR-378i in lesional compared to non-lesional skin before treatment. During treatment, the circRNAs progressively returned to the expression levels observed in non-lesional skin and already four days after treatment initiation most circRNAs were significantly upregulated. In comparison, for miRNAs, the normalization to baseline during treatment was delayed and limited to a subset of miRNAs. Moreover, we observed a strong correlation between multiple circRNAs, including ciRS-7 and circPTPRA, and the psoriasis area and severity index (PASI). Similar pronounced correlations could, however, not be found for miRNAs. Finally, we did not observe any significant changes in circRNA expression in peripheral blood mononuclear cells during treatment. In conclusion, we uncovered a rapid shift in global circRNA abundance upon anti-IL-17A treatment, which predated clinical and histological improvements, and a strong correlation with PASI, indicating a biomarker potential of individual circRNAs.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies, Monoclonal, Humanized
  • Humans
  • Leukocytes, Mononuclear
  • MicroRNAs* / genetics
  • Psoriasis* / drug therapy
  • Psoriasis* / genetics
  • RNA, Circular* / genetics

Substances

  • Antibodies, Monoclonal, Humanized
  • MicroRNAs
  • RNA, Circular
  • secukinumab

Grants and funding

This project was supported by the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie [grant no. 721890; J.K.; https://marie-sklodowska-curie-actions.ec.europa.eu/], the Leo Foundation [grant no. LF-OC-20-000376; L.S.K.; https://leo-foundation.org/en/], Villum Foundation [grant no. 00013393; J.K.; https://veluxfoundations.dk/en], and Lundbeck foundation [grant no. R307-2018-3433; L.S.K.; https://lundbeckfonden.com/en]. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.